AALL1521: INCB 18424-269 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia (ALL)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Acute Lymphoblastic Leukemia
-
Age: Between 2 years - 21 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1. Patients must have newly diagnosed HR Ph-like B-ALL meeting any of the following:
Patients ≥ 10 years at diagnosis
WBC ≥ 50 X 10^3/µL
CNS3 leukemia at diagnosis
2. Patients must have completed a 4-drug regimen Induction therapy
3. Patients should have eligible genetic alterations (please contact study PI for details)
You may not be eligible for this study if the following are true:
-
1. Receipt of any other cytotoxic chemotherapy before Induction therapy; prior treatment with a JAK inhibitor for any indication
2. Patients with BCR-ABL1-rearranged ALL
3. Patients with Trisomy 21; other malignancy in addition to ALL, or secondary ALL
4. Patients with chronic or current active infectious disease requiring systemic antibiotics, antifungal treatment, or antiviral treatment that is not well-controlled or resolving
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.